UNAIDS applauds today’s agreement between the Clinton Foundation and four generic pharmaceutical companies -- Aspen Pharmacare Holdings, Cipla, Ranbaxy Laboratories, and Matrix Laboratories -- to dramatically lower the price of HIV/AIDS treatment in the developing world. This builds on the Clinton Foundation’s work with the governments of several countries in Africa and the Caribbean to develop plans to strengthen their health care systems.